Literature DB >> 30761458

Twenty-four-hour urine NE level as a predictor of the therapeutic response to metoprolol in children with recurrent vasovagal syncope.

Qingyu Kong1, Xiaofei Yang2, Zhifeng Cai1, Yanyan Pan3, Minmin Wang1, Mengmeng Liu1, Cuifen Zhao4.   

Abstract

BACKGROUND: Vasovagal syncope (VVS) is a heterogeneous disorder that creates challenges for treatment. Metoprolol is an important therapeutic option for children with VVS. AIMS: The study examined the predictive value of 24-h urine norepinephrine (NE) levels in the assessment of the therapeutic efficacy of metoprolol for recurrent VVS in children.
METHODS: Thirty-eight children with recurrent VVS and 20 healthy children were enrolled in our study. Twenty-four-hour urine NE levels were measured by LC-MS-MS. VVS children were diagnosed by BHUTT and/or SNHUTT, and received metoprolol treatment for 3 months. Symptom scoring was utilized to evaluate the therapeutic effect. A ROC curve was used to investigate the predictive value of 24-h urine norepinephrine levels.
RESULTS: There exists significant correlation between 24-h urine NE levels and supine systolic and diastolic blood pressures. The 24-h urine NE levels of responders (40.75 ± 12.86 μg/24 h) were higher than those of nonresponders (21.48 ± 6.49 μg/24 h), and there was a significant difference between the two groups (P < 0.001). A ROC curve of the predictive value of 24 h urine NE levels revealed that the area under the curve was 0.926. A cutoff value for 24-h urine NE level of 34.84 μg/24 h produced both high sensitivity (70%) and specificity (100%) in predicting the efficacy of metoprolol therapy for VVS.
CONCLUSIONS: Patients with high 24-h urine NE levels have higher supine systolic and diastolic pressures and more effective responses to metoprolol. A 24-h urine norepinephrine level of > 34.84 μg/24 h was an indicator of the effectiveness of metoprolol therapy for VVS in children.

Entities:  

Keywords:  Children; Metoprolol; Norepinephrine; Recurrent vasovagal syncope; Urine

Mesh:

Substances:

Year:  2019        PMID: 30761458     DOI: 10.1007/s11845-019-01979-9

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  30 in total

Review 1.  The management of vasovagal syncope.

Authors:  S W Parry; R A Kenny
Journal:  QJM       Date:  1999-12

2.  Excretion of noradrenaline in urine in hypertension.

Authors:  U S VON EULER; S HELLNER; A PURKHOLD
Journal:  Scand J Clin Lab Invest       Date:  1954       Impact factor: 1.713

3.  A multi-center study of hemodynamic characteristics exhibited by children with unexplained syncope.

Authors:  Li Chen; Yuan-yuan Yang; Cheng Wang; Hong-wei Wang; Hong Tian; Qing-you Zhang; Jian-jun Chen; Yu-li Wang; Yi-long Kang; Chao-shu Tang; Jun-bao Du
Journal:  Chin Med J (Engl)       Date:  2006-12-20       Impact factor: 2.628

4.  Plasma hydrogen sulfide in differential diagnosis between vasovagal syncope and postural orthostatic tachycardia syndrome in children.

Authors:  Fengwen Zhang; Xueying Li; Chen Stella; Li Chen; Ying Liao; Chaoshu Tang; Hongfang Jin; Junbao Du
Journal:  J Pediatr       Date:  2011-09-13       Impact factor: 4.406

5.  Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers.

Authors:  T Klingenheben; S Credner; S H Hohnloser
Journal:  Pacing Clin Electrophysiol       Date:  1999-02       Impact factor: 1.976

6.  Oral fluid therapy. A promising treatment for vasodepressor syncope.

Authors:  A K Younoszai; W H Franklin; D P Chan; S C Cassidy; H D Allen
Journal:  Arch Pediatr Adolesc Med       Date:  1998-02

7.  Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.

Authors:  M Biffi; G Boriani; P Sabbatani; G Bronzetti; L Frabetti; R Zannoli; A Branzi; B Magnani
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

8.  A randomized and controlled pilot trial of beta-blockers for the treatment of recurrent syncope in patients with a positive or negative response to head-up tilt test.

Authors:  Rodolfo Ventura; Renke Maas; Daniel Zeidler; Volker Schoder; Cristhoph A Nienaber; Andreas Schuchert; Thomas Meinertz
Journal:  Pacing Clin Electrophysiol       Date:  2002-05       Impact factor: 1.976

Review 9.  Liquid chromatographic methods for the quantification of catecholamines and their metabolites in several biological samples--a review.

Authors:  Joana Bicker; Ana Fortuna; Gilberto Alves; Amílcar Falcão
Journal:  Anal Chim Acta       Date:  2012-12-27       Impact factor: 6.558

10.  Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design.

Authors:  R Sheldon; S Rose; S Connolly
Journal:  Europace       Date:  2003-01       Impact factor: 5.214

View more
  5 in total

Review 1.  Pathophysiology and Individualized Management of Vasovagal Syncope and Postural Tachycardia Syndrome in Children and Adolescents: An Update.

Authors:  Ying Liao; Junbao Du
Journal:  Neurosci Bull       Date:  2020-05-04       Impact factor: 5.203

2.  Baroreflex Sensitivity Predicts Response to Metoprolol in Children With Vasovagal Syncope: A Pilot Study.

Authors:  Chunyan Tao; Xueying Li; Chaoshu Tang; Hongfang Jin; Junbao Du
Journal:  Front Neurosci       Date:  2019-12-13       Impact factor: 4.677

3.  Poincaré Plot Can Be a Useful Tool to Select Potential Responders to Metoprolol Therapy in Children with Vasovagal Syncope.

Authors:  Piaoliu Yuan; Xueying Li; Chunyan Tao; Xiaojuan Du; Chunyu Zhang; Junbao Du; Yaqian Huang; Ying Liao
Journal:  Int J Gen Med       Date:  2022-03-08

Review 4.  Biomarkers and Hemodynamic Parameters in the Diagnosis and Treatment of Children with Postural Tachycardia Syndrome and Vasovagal Syncope.

Authors:  Wenjie Cheng; Jiaqi Wang; Jing Lin
Journal:  Int J Environ Res Public Health       Date:  2022-06-07       Impact factor: 4.614

5.  Clinical Efficacy of Empirical Therapy in Children with Vasovagal Syncope.

Authors:  Chunyan Tao; Yaxi Cui; Chunyu Zhang; Xueqin Liu; Qingyou Zhang; Ping Liu; Yuli Wang; Junbao Du; Hongfang Jin
Journal:  Children (Basel)       Date:  2022-07-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.